Persistent Pulmonary Hypertension of the Newborn at Nakhon Phanom Hospital

Authors

  • Charinporn Panaarunwong Department of Pediatrics, Nakhon Phanom Hospital

Keywords:

newborn, persistent pulmonary hypertension of the newborn

Abstract

his retrospective study was to review patients with persistent pulmonary hypertension of the newborn (PPHN) at Nakhon phanom hospital from April 2011 to May 2017. The purpose of this study was to describe the prevalence, demographic pattern, clinical description, treatment, complication outcome and mortality rate. The results howed that the prevalence of persistent pulmonary hypertension of the newborn were 1.12 – 2.96 per 1,000 live births. 19 of 32 diagnosed PPHN newborns were males (59.40%). Thai nationality 28 cases (87.50%). 56.20% were delivered by normal labour. 13 newborns (40.60%) were transfer from other hospitals with average age 5.17 hours. The average gestational age were 40.42 ± 2.56 weeks, birth weight 3,243.13 ± 665.72 grams and the Apgar score at 1, 5 and 10 minutes were 6.42 ± 3.12, 7.90 ± 2.55 และ 8.50 ± 2.36 respectively. The diagnosed PPHN age was 6.19 (0.33 – 30) hours. The most common cause of PPHN was MAS (78.10%). The PPHN newborns were on CMV setting MAX PIP 17 ± 2.58 cmH2O, MAX PEEP 4.13 ± 0.92 cmH2O and mandatory rate 80.65 ± 19.65 times/minute. Max mean airway pressure and amplitude in HFOV setting were 18.45 ± 4.96 cmH2O and 33.40 ± 7.34 respectively. The newborns received crystalloid (NSS) 29 cases (90.62%), FFP 23 cases (71.90%), PRC 12 cases (37.50%) and NaHCO3 10 cases (31.25%). All of them received inotropic drugs. The average dose of dopamine, dobutamine, epinephrine and norepinephrine were 17.97 ± 3.99, 18.91 ± 3.00, 1.48 ± 0.87 and 1.61 ± 0.47 mcg/kg/min respectively. MgSO4, sildenafil, intravenous iloprost and iloprost with milrinone were used for pulmonary blood pressure reducing in PPHN newborns for 5 cases (15.60%), 7 cases (21.90%), 5 cases (15.60%) and 1 cases (3.10%) respectively. Gastrointestinal bleeding was found 34.40% as the most common complication in this study. Mortality rate was 59.40%. The died newborns group had higher SBP, MAP than the survivor group with statistically significant (p < 0.05) and shorter length of stays than the survivor group with statistically significant (p < 0.01). The followed survivors had normal development at 2 years old was 57.14% and delayed development 1 case (14.29%). Conclusion The mortality rate of PPHN was high. The majority cause was meconium aspiration syndrome that could be preventable. Therefore, the development of healthcare personnel knowledge, skill performance and effective neonatal care networks should be established for decrease in mortality rate.

References

Walsh MC, tock EK. Persistent pulmonary of newborn: rational therapy base on pathophysiology. Clin Perinatol 2001;28(3):609-627.

Khorana M, Yookaseam T, Layangool T, Kanjanapattanakul W, Paradeevisut H. Outcome of oral sildenafil therapy on persistent pulmonary hypertension of the newborn at Queen Sirikit National Institute of Child Health. J Med Assoc Thai 2011;94 Suppl 3: S64-73.

Nakwan N, Pithaklimnuwong S. Acute kidney injury and pneumothorax are risk factors for mortality in persistent pulmonary hypertension of the newborn in Thai neonates. J Matern Fetal Neonatal Med 2016;29(11):1741-6.

Chotigeat U, Jaratwashirakul S. Inhaled iloprost for severe persistent pulmonary hypertension of the newborn. J Med Assoc Thai 2007;90(1):167-70.

Barbara JS, Robirt MK. Respiratory tract disorders. Nelson textbook of pediatrics 17 th edition 2004;584-6.

Chotigeat U, Khorana M, Kanjanapattanakul W. Outcome of neonates with persistent pulmonary hypertension of the newborn treated with inhaled nitric oxide. J Med Assoc Thai 2002;85(7

Barrington KJ, Finer N, Pennaforte T, Altit G. Nitric oxide for respiratory failure in infants born at or near term. Cochrane Database Syst Rev 2017;5;1:CD000399. doi 10. 1002/14651858. CD000399.pub3.

งานเวชระเบียนและสถิติ โรงพยาบาลนครพนม. รายงานเวชสถิติโรงพยาบาลนครพนมประจําปี 2559. นครพนม : โรงพยาบาลนครพนม; 2560.

Ann R Stark , Eric C Eichenwald. Persistent pulmonary hypertension of newborn. (serial online) (Cite 2017 Mar 14) Available from : URL: // w.w.w. uptodate.com

อุกฤษฎ์ จิระปิติ, วรางคณา มหาพรหม. ลักษณะทางคลินิกของผู้ป่วยทารกแรกเกิดที่มีภาวะความดัน โลหิตในปอดสูงในโรงพยาบาลเชียงรายประชานุเคราะห์. เชียงรายเวชสาร 2557; 6(1): 57-66.

Joaquim EB, Jaques B. Persistent pulmonary hypertension of the newborn: recent advances in pathophysiology and treatment. J Pediatr (Rio J) 2013;89(3):226-242

อุไรวรรณ โชติเกียรติ, มิรา โครานา, วิบูลย์ กาญจนพัฒนกุล, วราภรณ์ แสงทวีสิน, สุนทร ฮ้อเผ่าพันธุ์. ผลการ รักษาความดันหลอดเลือดปอดสูงในเด็กทารก (PPHN) ด้วยเครื่องช่วยหายใจความถี่สูง(HFOV): ประสบการณ์ 5 ปี. วารสาร กุมารเวชศาสตร์ 2546; 42: 1-8.

อุไรวรรณ โชติเกียรติ, วราภรณ์ แสงทวีสิน, วิบูลย์ กาญจนพัฒนกุล, สุนทร ฮ้อเผ่าพันธุ์, วิไล ราตรี สวัสดิ์. ผลการรักษา Persistent pulmonary hypertension of newborn. วารสารกุมารเวชศาสตร์ 2542; 38: 200-8.

Martina AS, Laura LJ, Rebecca JB, Colin P, Elizabeth ER, Roberta LK. Persistent pulmonary hypertension of the newborn in late preterm and term infants in California. Pediatrics 2017;139(1): e20161165

วรนาฏ จันทร์ขจร. ภาวะความดันเลือดปอดสูงในทารกแรกเกิดในโรงพยาบาลขอนแก่น. ขอนแก่นเวชสาร. 2549; 30:151-8.

Downloads

Published

2017-08-30

How to Cite

1.
Panaarunwong C. Persistent Pulmonary Hypertension of the Newborn at Nakhon Phanom Hospital. Nakhonphanom Hosp J [internet]. 2017 Aug. 30 [cited 2026 Jan. 27];4(2):5-18. available from: https://he01.tci-thaijo.org/index.php/nkpjournal_9/article/view/254603

Issue

Section

Original article